Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice
Huihui Ma, … , Suzanne Lentzsch, Markus Y. Mapara
Huihui Ma, … , Suzanne Lentzsch, Markus Y. Mapara
Published June 13, 2011
Citation Information: J Clin Invest. 2011;121(7):2554-2569. https://doi.org/10.1172/JCI43706.
View: Text | PDF | Corrigendum
Research Article Hematology

Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice

  • Text
  • PDF
Abstract

STAT1 is the main signal transducer for type I and II IFNs and plays a central role in the regulation of innate and adaptive immune responses. We used Stat1-deficient mice to test the role of donor Stat1 in MHC-matched minor histocompatibility antigen–mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marrow transplantation. Lack of Stat1 in donor splenocytes reduced graft-versus-host disease (GVHD) in both immunogenetic disparities, leading to substantially attenuated morbidity and mortality. Donor Stat1 deficiency resulted in reduced alloantigen-induced activation and expansion of donor T cells and correlated with the expansion of CD4+CD25+Foxp3+ Tregs in vivo. This expansion of Tregs was further confirmed by studies showing that Stat1 deficiency promoted the proliferation, while inhibiting the apoptosis, of natural Tregs, and that absence of Stat1 enhanced the induction of inducible Tregs both in vitro and in vivo. Ex vivo expanded Stat1–/– Tregs were superior to wild-type Tregs in suppressing alloantigen-driven expansion of T cells in vitro and in inhibiting the development of GVHD. These observations demonstrate that Stat1 is a regulator of Tregs and that targeting Stat1 in CD4+ T cells may facilitate in vitro and in vivo expansion of Tregs for therapeutic use.

Authors

Huihui Ma, Caisheng Lu, Judith Ziegler, Ailing Liu, Antonia Sepulveda, Hideho Okada, Suzanne Lentzsch, Markus Y. Mapara

×

Figure 1

Stat1-deficiency in donor spleen cells leads to reduced GVHD.

Options: View larger image (or click on image) Download as PowerPoint
Stat1-deficiency in donor spleen cells leads to reduced GVHD.
(A) mHA-mi...
(A) mHA-mismatched GVHD. B6 mice received 5 × 106 BMCs and 4 × 107 splenocytes (SPCs) from 129.Stat1–/– or 129.Stat1+/+ mice. B6 mice receiving BMCs from B6, 129.Stat1+/+, or 129.Stat1–/– mice were used as controls. Recipients of 129.Stat1–/– BMCs and splenocytes were protected from GVHD-induced mortality compared with wild-type recipients (MST not reached versus 51-day MST; P = 0.023). (B) Clinical GVHD scores on days 6 and 30 following mHA-mismatched BMT. Data are representative of 1 of 2 independent experiments (n = 6–7/group). (C) Fully MHC-mismatched GVHD (129Sv[H2b] to BALB/c [H2d]) strain combination using 129.Stat1–/– or 129.Stat1+/+ splenocytes. BALB/c mice receiving BMCs from BALB/c, 129.Stat1+/+, or 129.Stat1–/– mice were used as controls. (D) Clinical GVHD scores on day 6 after MHC-mismatched BMT. Data are representative of 1 of 3 similar experiments (n = 5–10/group). (E) Delayed mortality following GVHD induction in BALB/c recipients using purified CD4+ T cells (3 × 106) from 129.Stat1+/+ or 129.Stat1–/– mice and BMT with 5 × 106 TCD Stat1+/+ BMCs. Recipients of BALB/c or 129.Stat1+/+ BMCs were used as controls. Mortality was significantly delayed in recipients of 129.Stat1–/– CD4+ T cells (MST 7.5 days versus 21 days; P = 0.037). (F) Clinical GVHD score on day 6 after BMT. Data are representative of 1 of 2 similar experiments (n = 5/group). Clinical scores for individual animals are shown in B, D, and F. Horizontal bars denote the mean of clinical scores.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts